Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorTempero, Margaret A.
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorReni, Michele
dc.contributor.authorVan Cutsem, Eric
dc.contributor.authorHendifar, Andrew E.
dc.contributor.authorMacarulla Mercadé, Teresa
dc.contributor.authorOh, Do-Youn
dc.date.accessioned2022-06-17T10:54:57Z
dc.date.available2022-06-17T10:54:57Z
dc.date.issued2021-05
dc.identifier.citationTempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol. 2021 May;32(5):600–8.
dc.identifier.issn0923-7534
dc.identifier.urihttps://hdl.handle.net/11351/7711
dc.descriptionIbrutinib; Adenocarcinoma de pàncrees metastàtic; Fase III
dc.description.sponsorshipThis work was supported by Pharmacyclics LLC, an AbbVie Company (no grant number).
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesAnnals of Oncology;32(5)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPàncrees - Càncer - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectQuimioteràpia combinada
dc.subject.meshPancreatic Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshTreatment Outcome
dc.titleIbrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.annonc.2021.01.070
dc.subject.decsneoplasias pancreáticas
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1016/j.annonc.2021.01.070
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Tempero M] Department of Medicine, University of California San Francisco, San Francisco, USA. [Oh DY] Department of Internal Medicine, Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. [Tabernero J, Macarulla T] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UICC, CIBERONC, Barcelona, Spain. [Reni M] Department of Radiochemotherapy, San Raffaele Hospital Scientific Institute, Milan, Italy. [Van Cutsem E] Department of Digestive Oncology, University Hospitals Gasthuisberg/Leuven & KU Leuven, Leuven, Belgium. [Hendifar A] Department of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, USA
dc.identifier.pmid33539945
dc.identifier.wos000640355800006
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple